Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | GLA | P06280 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7394651 | 0.82 | RAB9A (0.63) | GAANPC1RAB9ATSHRGLA | |
| SCHEMBL3869373 | 0.82 | GAA (0.57) | GAANPC1RAB9ATSHRGLA | |
| SCHEMBL7323777 | 0.81 | GAA (0.42) | GAANPC1RAB9ATSHRGLA | |
| Hydrochloric Acid SCHEMBL3869366 | 0.81 | GAA (0.56) | GAANPC1RAB9ATSHRGLA | |
| SCHEMBL3814103 | 0.79 | GAA (0.69) | GAANPC1RAB9ATSHRKDM4E | |
| SCHEMBL5857396 | 0.78 | TSHR (0.64) | GAANPC1RAB9ATSHRKDM4E | |
| SCHEMBL2330242 | 0.78 | GAA (0.82) | GAANPC1RAB9ATSHRHTT | |
| SCHEMBL26970100 | 0.77 | NPSR1 (0.58) | GAANPC1RAB9AL3MBTL1KDM4E | |
| SCHEMBL28929407 | 0.76 | RAB9A (0.71) | GAANPC1RAB9AL3MBTL1HPGD | |
| SCHEMBL2199589 | 0.76 | GAA (0.69) | GAANPC1RAB9ATSHRGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10266542-B2 | EZH2 inhibitors | Mirati Therapeutics, Inc. (US) | 2019-04-23 | — | — | US | disclosed |
| EP-0528633-B1 | Pyrimidinyl acetamides as elastase inhibitors | ZENECA LTD (GB) | 2000-10-18 | — | — | EP | disclosed |
| US-5254558-A | Substituted 1,3-diazines as leukocyte elastase inhibitors | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-10-19 | — | — | US | disclosed |
| EP-0528633-A1 | Pyrimidinyl acetamides as elastase inhibitors | ZENECA LIMITED (GB) | 1993-02-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10266542-B2 | EZH2 inhibitors | EZH2, BMI1, EED | GAA 3179/4885NPC1 2007/4885RAB9A 1568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.